Skip to content

LACE+ and MRS Score Readmission Rate Assessment

Comparing the Predictive Strength of the LACE+ Index With the MedWise Rise Score on Hospital Readmission Rates: a Non-inferiority Observational Study

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04365673
Enrollment
100
Registered
2020-04-28
Start date
2020-07-07
Completion date
2021-03-01
Last updated
2022-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hospitalism

Keywords

LACE, medication risk score

Brief summary

A study to demonstrate that the LACE+ score in non-inferior to the medication risk score when predicting 30-day readmission post hospital discharge.

Detailed description

The objective of this study is evaluate a program that provides transition of care services to a local Tucson hospital involving activities designed to reduce 30 day post hospital discharge readmission rates. The organization has had a fee for service contract with this hospital since 2017 to provide pharmacist delivered transition of care services. The organization collects internal tracking outcome data as part of the contract deliverable and is required to report it to the hospital once per month. The investigators look to assess LACE+ and medication risk scores to learn if there is an association with the 30 day post hospital discharge readmission rate post pharmacist intervention. The outcomes will not be generalizable and will be reported back to the hospital client to demonstrate value added.

Interventions

OTHERPharmacist transition of care consultation

Pharmacist-delivered comprehensive medication review

Sponsors

Tabula Rasa HealthCare
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 88 Years
Healthy volunteers
No

Inclusion criteria

* Those referred to receive transition of care services between January 2018 to December 2019 and were discharged on 10 or more medications.

Exclusion criteria

* 89 years or older

Design outcomes

Primary

MeasureTime frameDescription
Readmission2018 - 2019Readmission within 30-days post hospital discharge

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026